Survival data justifies resection for pancreatic metastases

Area of Science:

• Surgical Oncology
• Gastrointestinal Oncology
• Metastatic Disease Research

Background:

• Pancreatic metastases are rare, with limited understanding of outcomes and prognostic factors post-resection.
• This study addresses the need for data on perioperative results and long-term survival following pancreatic metastasis resection.

Purpose of the Study:

• To evaluate perioperative and follow-up results after surgical resection of pancreatic metastases.
• To identify prognostic factors influencing overall and disease-free survival in these patients.

Main Methods:

• Analysis of a prospective database of consecutive pancreatic metastasis resections (October 2001 - July 2008).
• Collection and analysis of clinicopathological details, perioperative outcomes, and follow-up data.
• Uni- and multivariate analyses were conducted to determine survival predictors.

Main Results:

• Forty-four resections were performed, predominantly for renal cell carcinoma (RCC) metastases (70%).
• Morbidity was 33% and mortality 4.4%. Median follow-up was 32.1 months.
• Overall 3- and 5-year survival rates were 70.2% and 56.8%, respectively. Isolated metastases showed significantly better survival (85.6% and 74.9% at 3 and 5 years).
• Factors associated with shorter survival included additional extrapancreatic disease, short disease-free interval (<36 months), and non-RCC primary tumors.

Conclusions:

• Surgical resection of pancreatic metastases is a safe procedure with favorable outcomes.
• It is recommended as part of an interdisciplinary treatment approach.
• Long-term survival is achievable, especially for patients with isolated pancreatic metastases.